Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) say they will supply Japan with 120M doses of their mRNA-based vaccine candidate against the coronavirus in H1 2021; financial details are not disclosed.
The companies say they are on track to seek regulatory review for the vaccine as early as this October, with a goal of manufacturing up to 100M doses for use globally by the end of 2020.
Earlier this week, Pfizer and BioNTech announced the start of late-stage human trials for their BNT162b2 vaccine candidate.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.